recent publications
-
academic article
- Chun, J., Brinkmann, V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) Discovery Medicine 2011 64:213-228 PMID:21955849 PMCID:PMC3694567
- Salomone, S., Potts, E. M., Tyndall, S., Ip, P. C., Chun, J., Brinkmann, V., Waeber, C. Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools British Journal of Pharmacology 2008 153:140-147 DOI:10.1038/sj.bjp.0707581 PMID:18026125 PMCID:PMC2199385
- Walter, D. H., Rochwalsky, U., Reinhold, J., Seeger, F., Aicher, A., Urbich, C., Spyridopoulos, I., Chun, J., Brinkmann, V., Keul, P., Levkau, B., Zeiher, A. M., et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27:275-282 DOI:10.1161/01.atv.0000254669.12675.70 PMID:17158356
- Tolle, M., Levkau, B., Keul, P., Brinkmann, V., Giebing, G., Schonfelder, G., Schafers, M., Lipinski, K. V., Jankowski, J., Jankowski, V., Chun, J., Zidek, W., et al. Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3 Circulation Research 2005 96:913-920 DOI:10.1161/01.res.0000164321.91452.00 PMID:15802614